{
    "clinical_study": {
        "@rank": "58868", 
        "arm_group": [
            {
                "arm_group_label": "LY3050258", 
                "arm_group_type": "Experimental", 
                "description": "Daily dose of LY2624803 for 28 days."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Daily dose of placebo matching LY2624803 for 28 days."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multiple dose study of LY3050258 in healthy men and postmenopausal women.  This\n      study will evaluate the safety and  how well the body tolerates LY3050258.  It will last\n      approximately 14 weeks with a 2 week follow-up appointment after the last treatment with\n      study drug."
        }, 
        "brief_title": "A Study of LY3050258 in Healthy Participants", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy males or healthy postmenopausal females, including Japanese participants\n\n          -  Body mass index (BMI) of 18 and 35 kilograms per square meter (kg/m^2), inclusive\n\n        Exclusion Criteria:\n\n          -  Abnormal siting blood pressure as determined by the investigator\n\n          -  Abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the\n             investigator, places the participant at an unacceptable risk for study participation\n\n          -  Aspartate aminotransferase (AST) or alkaline phosphatase (ALT) greater than 2 times\n             the upper limit of normal (ULN)\n\n          -  Skin condition that in the opinion of the investigator makes the participant\n             unsuitable for study participation\n\n          -  Current use of statins within the last 3 months prior to dosing\n\n          -  Current use or previous use of anabolic steroids in the preceding 6 months prior to\n             dosing\n\n          -  Use of dehydroepiandrosterone, other potential over-the-counter steroidal\n             supplements, or other nutritional products intended to have weight-reduction and/or\n             performance-enhancing effects within 21 days prior to dosing"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02121834", 
            "org_study_id": "14936", 
            "secondary_id": "I6R-MC-DLAB"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "LY3050258", 
                    "Placebo"
                ], 
                "intervention_name": "LY3050258", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "LY3050258", 
                    "Placebo"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 22, 2014", 
        "location": {
            "contact": {
                "last_name": "Eli Lilly"
            }, 
            "facility": {
                "address": {
                    "city": "Cypress", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90630"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multiple-Dose, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of LY3050258", 
        "overall_contact": {
            "last_name": "This is a single site clinical trial. 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline to study completion (approximately 14 weeks)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02121834"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of Multiple Doses of LY3050258", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 4 weeks"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Maximum Concentration (Cmax) of Multiple Doses of LY3127760", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 4 weeks"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}